Hermine Poghosyan1,2, Michaela A Dinan3, Gevorg Tamamyan4,5,6,7, LaRon Nelson8,9, Sangchoon Jeon8. 1. Yale School of Nursing, Yale University, New Haven, CT, USA. Hermine.poghosyan@yale.edu. 2. Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, Yale Cancer Center and Yale University School of Medicine, New Haven, CT, USA. Hermine.poghosyan@yale.edu. 3. Yale School of Public Health, Co-Leader of the Cancer Prevention and Control Research Program, Yale Comprehensive Cancer Center, Yale School of Medicine, New Haven, CT, USA. 4. Institute of Cancer and Crisis, Yerevan, Armenia. 5. Pediatric Cancer and Blood Disorders Center of Armenia, Hematology Center After Prof. R.H. Yeolyan, Yerevan, Armenia. 6. Department of Pediatric Oncology and Hematology, Yerevan State Medical University, Yerevan, Armenia. 7. Immune Oncology Research Institute, Yerevan, Armenia. 8. Yale School of Nursing, Yale University, New Haven, CT, USA. 9. Global Affairs & Planetary Health Independence Foundation, Yale School of Nursing, Yale University, New Haven, CT, USA.
Abstract
BACKGROUND: The purpose of this study was to estimate COVID-19 vaccination rate among Medicare beneficiaries with cancer history and determine whether COVID-19 vaccine uptake is higher among non-Hispanic White beneficiaries compared with racially and ethnically minoritized beneficiaries. METHODS: We used US representative, cross-sectional data from the Medicare Current Beneficiary Survey COVID-19 Winter 2021 Rapid Response Community Supplement Survey. A total of 1,863 respondents with self-reported cancer history (other than skin cancer) were included. The outcome was self-reported receipt of at least one coronavirus vaccine dose since vaccines became available. The key independent variable of interest was self-reported race and ethnicity. We applied sample weights to account for the survey design and provide population estimates to 9.6 million beneficiaries with cancer history. Weighted descriptive statistics and multivariable logistic regression analyses were conducted. RESULTS: During the first 4 months of vaccine availability, 69.6% of beneficiaries received at least one vaccine dose of which 65.4% had two vaccine doses. A larger proportion of non-Hispanic White beneficiaries (71.9%) had at least one vaccine dose compared with non-Hispanic Black (60.4%) and Hispanic (57.4%) beneficiaries. An estimated 30.4% of beneficiaries were still unvaccinated, that represents approximately 2.9 million unvaccinated beneficiaries with cancer history. Hispanic beneficiaries were 42% (OR: 0.58; 95% CI: 0.33-0.99; p = .048) less likely to be vaccinated compared with non-Hispanic White beneficiaries. CONCLUSIONS: Results indicate racial and ethnic differences in vaccine uptake among Medicare beneficiaries with cancer history. Effective strategies are needed to help increase vaccine confidence and uptake among adults with cancer history.
BACKGROUND: The purpose of this study was to estimate COVID-19 vaccination rate among Medicare beneficiaries with cancer history and determine whether COVID-19 vaccine uptake is higher among non-Hispanic White beneficiaries compared with racially and ethnically minoritized beneficiaries. METHODS: We used US representative, cross-sectional data from the Medicare Current Beneficiary Survey COVID-19 Winter 2021 Rapid Response Community Supplement Survey. A total of 1,863 respondents with self-reported cancer history (other than skin cancer) were included. The outcome was self-reported receipt of at least one coronavirus vaccine dose since vaccines became available. The key independent variable of interest was self-reported race and ethnicity. We applied sample weights to account for the survey design and provide population estimates to 9.6 million beneficiaries with cancer history. Weighted descriptive statistics and multivariable logistic regression analyses were conducted. RESULTS: During the first 4 months of vaccine availability, 69.6% of beneficiaries received at least one vaccine dose of which 65.4% had two vaccine doses. A larger proportion of non-Hispanic White beneficiaries (71.9%) had at least one vaccine dose compared with non-Hispanic Black (60.4%) and Hispanic (57.4%) beneficiaries. An estimated 30.4% of beneficiaries were still unvaccinated, that represents approximately 2.9 million unvaccinated beneficiaries with cancer history. Hispanic beneficiaries were 42% (OR: 0.58; 95% CI: 0.33-0.99; p = .048) less likely to be vaccinated compared with non-Hispanic White beneficiaries. CONCLUSIONS: Results indicate racial and ethnic differences in vaccine uptake among Medicare beneficiaries with cancer history. Effective strategies are needed to help increase vaccine confidence and uptake among adults with cancer history.
Authors: Kevin Kalinsky; Melissa K Accordino; Kristina Hosi; Jessica E Hawley; Meghna S Trivedi; Katherine D Crew; Dawn L Hershman Journal: Breast Cancer Res Treat Date: 2020-05-14 Impact factor: 4.872
Authors: Nicole M Kuderer; Toni K Choueiri; Dimpy P Shah; Yu Shyr; Samuel M Rubinstein; Donna R Rivera; Sanjay Shete; Chih-Yuan Hsu; Aakash Desai; Gilberto de Lima Lopes; Petros Grivas; Corrie A Painter; Solange Peters; Michael A Thompson; Ziad Bakouny; Gerald Batist; Tanios Bekaii-Saab; Mehmet A Bilen; Nathaniel Bouganim; Mateo Bover Larroya; Daniel Castellano; Salvatore A Del Prete; Deborah B Doroshow; Pamela C Egan; Arielle Elkrief; Dimitrios Farmakiotis; Daniel Flora; Matthew D Galsky; Michael J Glover; Elizabeth A Griffiths; Anthony P Gulati; Shilpa Gupta; Navid Hafez; Thorvardur R Halfdanarson; Jessica E Hawley; Emily Hsu; Anup Kasi; Ali R Khaki; Christopher A Lemmon; Colleen Lewis; Barbara Logan; Tyler Masters; Rana R McKay; Ruben A Mesa; Alicia K Morgans; Mary F Mulcahy; Orestis A Panagiotou; Prakash Peddi; Nathan A Pennell; Kerry Reynolds; Lane R Rosen; Rachel Rosovsky; Mary Salazar; Andrew Schmidt; Sumit A Shah; Justin A Shaya; John Steinharter; Keith E Stockerl-Goldstein; Suki Subbiah; Donald C Vinh; Firas H Wehbe; Lisa B Weissmann; Julie Tsu-Yu Wu; Elizabeth Wulff-Burchfield; Zhuoer Xie; Albert Yeh; Peter P Yu; Alice Y Zhou; Leyre Zubiri; Sanjay Mishra; Gary H Lyman; Brian I Rini; Jeremy L Warner Journal: Lancet Date: 2020-05-28 Impact factor: 79.321
Authors: P Grivas; A R Khaki; T M Wise-Draper; B French; C Hennessy; C-Y Hsu; Y Shyr; X Li; T K Choueiri; C A Painter; S Peters; B I Rini; M A Thompson; S Mishra; D R Rivera; J D Acoba; M Z Abidi; Z Bakouny; B Bashir; T Bekaii-Saab; S Berg; E H Bernicker; M A Bilen; P Bindal; R Bishnoi; N Bouganim; D W Bowles; A Cabal; P F Caimi; D D Chism; J Crowell; C Curran; A Desai; B Dixon; D B Doroshow; E B Durbin; A Elkrief; D Farmakiotis; A Fazio; L A Fecher; D B Flora; C R Friese; J Fu; S M Gadgeel; M D Galsky; D M Gill; M J Glover; S Goyal; P Grover; S Gulati; S Gupta; S Halabi; T R Halfdanarson; B Halmos; D J Hausrath; J E Hawley; E Hsu; M Huynh-Le; C Hwang; C Jani; A Jayaraj; D B Johnson; A Kasi; H Khan; V S Koshkin; N M Kuderer; D H Kwon; P E Lammers; A Li; A Loaiza-Bonilla; C A Low; M B Lustberg; G H Lyman; R R McKay; C McNair; H Menon; R A Mesa; V Mico; D Mundt; G Nagaraj; E S Nakasone; J Nakayama; A Nizam; N L Nock; C Park; J M Patel; K G Patel; P Peddi; N A Pennell; A J Piper-Vallillo; M Puc; D Ravindranathan; M E Reeves; D Y Reuben; L Rosenstein; R P Rosovsky; S M Rubinstein; M Salazar; A L Schmidt; G K Schwartz; M R Shah; S A Shah; C Shah; J A Shaya; S R K Singh; M Smits; K E Stockerl-Goldstein; D G Stover; M Streckfuss; S Subbiah; L Tachiki; E Tadesse; A Thakkar; M D Tucker; A K Verma; D C Vinh; M Weiss; J T Wu; E Wulff-Burchfield; Z Xie; P P Yu; T Zhang; A Y Zhou; H Zhu; L Zubiri; D P Shah; J L Warner; G dL Lopes Journal: Ann Oncol Date: 2021-03-18 Impact factor: 32.976
Authors: Kamal S Saini; Marco Tagliamento; Matteo Lambertini; Richard McNally; Marco Romano; Manuela Leone; Giuseppe Curigliano; Evandro de Azambuja Journal: Eur J Cancer Date: 2020-09-02 Impact factor: 9.162
Authors: Annika Fendler; Elisabeth G E de Vries; Corine H GeurtsvanKessel; John B Haanen; Bernhard Wörmann; Samra Turajlic; Marie von Lilienfeld-Toal Journal: Nat Rev Clin Oncol Date: 2022-03-11 Impact factor: 65.011
Authors: Wenjuan He; Lei Chen; Li Chen; Guolin Yuan; Yun Fang; Wenlan Chen; Di Wu; Bo Liang; Xiaoting Lu; Yanling Ma; Lei Li; Hongxiang Wang; Zhichao Chen; Qiubai Li; Robert Peter Gale Journal: Leukemia Date: 2020-04-24 Impact factor: 12.883